Skip to main content
. 2015 Jan 6;23(4):341–351. doi: 10.1016/j.jsps.2014.08.004

Figure 8.

Figure 8

(A) Cell cycle analysis by Flow cytometry (a) untreated control, (b) Cisplatin IC20, (c) Cisplatin IC50, (d) nanoparticles IC20, (e) nanoparticles IC50 and (B) comparative evaluation of the percentage of cells after treatment in different cell cycle phases for the treatment groups in comparison with control (P < 0.001).